Although
rennet is one of the best choices for cheese manufacturing,
its production cannot meet the growing demands of the cheese industry.
Thus, new milk-clotting enzymes (MCEs) with similar or better properties
as/than those of calf chymosin are needed urgently. Here, three MCEs,
BY-2, BY-3, and BY-4, were mined by bioinformatic analysis and then
expressed in and isolated from Escherichia coli. BY-4 had the highest milk-clotting activity/proteolytic activity
(238.76) with enzyme properties similar to those of calf chymosin.
BY-4 cheese had a composition, appearance, consistency/texture, and
overall acceptability proximate to calf chymosin cheese. The EC50 values of peptides extracted from BY-4 cheese for 2,2-diphenyl-1-picrylhydrazyl
inhibition (antioxidant property), angiotensin-converting enzyme inhibition
(antihypertensivity), and growth inhibition of liver cancer cells
(antitumor property) were found to be 81, 49, and 238 μg/mL,
respectively, which were 2.35, 2.59, and 2.12 folds higher than those
of calf chymosin cheese. These results indicated the potential of
BY-4 as a supplement to calf chymosin in cheese manufacturing, especially
for functional and health care purposes.